Company: ARTL
Filing Date: 2025-12-11
Form Type: DEF 14A
Source: 0001640334-25-002308
Chunk: 0

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-12-11
Form: DEF 14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934</div>

☒ Filed by the Registrant

☐ Filed by a party other than the Registrant

Check the appropriate box:

| ☐ | Preliminary Proxy Statement                                                     |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) |
| ☒ | Definitive Proxy Statement                                                      |
| ☐ | Definitive Additional Materials                                                 |
| ☐ | Soliciting Material under §240.14a‑12                                           |

| ARTELO BIOSCIENCES, INC.                         |
| (Name of Registrant as Specified In Its Charter) |

<div align='center'>______________________________________________________

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required                                                                                     |
| ☐ | Fee paid previously with preliminary materials                                                      |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

<div align='center'>505 Lomas Santa Fe, Suite 160

Solana Beach, CA 92075

NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS</div>

To the Stockholders of Artelo Biosciences, Inc.:

Notice is hereby given that the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Artelo Biosciences, Inc., a Nevada corporation, will be held on Wednesday, December 31, 2025 at 8:00 a.m., Pacific Time, via internet webcast, for the following purposes:

| 1. | To elect two (2) Class II director nominees, Douglas Blayney, M.D., and Connie Matsui, to serve on the Board until the Company’s 2028 Annual Meeting of Stockholders, or until their successors are duly elected and qualified or until their earlier resignation or removal, as further described in Proposal No. 1 in the Company’s proxy statement; |
| 2. | To approve, on an advisory basis, the compensation of the named executive officers identified in